{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 13 of 129', '12.3.9.5 Anti-drug antibodies', '101', '12.3.10 Interim analysis', '101', '12.3.11 Analysis of data up to Week 32', '101', '12.3.12 General principles', '102', '12.3.13 Handling of missing values', '102', '13 References', '103', 'Appendix 1: Definitions of adverse events and serious adverse events', '107', 'Appendix 2: Classification of adverse events', '109', 'Appendix 3: Trial governance considerations', '111', 'Appendix 3A: Regulatory and ethical considerations', '111', 'Appendix 3B: Informed consent process', '111', 'Appendix 3C: Subject and data confidentiality', '112', 'Appendix 3D: Record keeping, quality control, and data handling', '113', 'Appendix 3E: Registration, reporting, and publication policy', '117', 'Appendix 3F: Insurance', '118', 'Appendix 3G: Financial disclosure', '118', 'Appendix 3H: Trial and site closure', '119', 'Appendix 3I: Responsibilities', '120', 'Appendix 4: Hanifin and Rajka (1980) diagnostic criteria for AD (21)', '121', 'Appendix 5: Guidance for anaphylaxis diagnosis (24)', '122', 'Appendix 6: Contact list', '123', 'Appendix 7: Protocol amendment history', '125', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 14 of 129', 'List of panels', 'Panel 1 Trial design', '21', 'Panel 2 Schedule of trial procedures: screening and treatment periods', '22', 'Panel 3 Schedule of trial procedures: follow-up including early termination', '25', 'Panel 4 Objectives and endpoints', '32', 'Panel 5 Identification of investigational medicinal products', '47', \"Panel 6 Investigator's Global Assessment\", '65', 'Panel 7 Calculation of the Eczema Area and Severity Index', '66', 'Panel 8 EASI severity score scale and area score scale', '66', 'Panel 9 Central laboratory testing', '74', 'Panel 10 Adverse events of special interest', '80', 'Panel 11 Testing procedure for primary and secondary endpoints', '86', 'Panel 12 Transmission of electronic data', '116', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 15 of 129', 'List of abbreviations', 'AD', 'atopic dermatitis', 'ADA', 'anti-drug antibodies', 'AE', 'adverse event', 'AESI', 'adverse event of special interest', 'ALT', 'alanine aminotransferase', 'AST', 'aspartate aminotransferase', 'BP', 'blood pressure', 'BSA', 'body surface area', 'CI', 'confidence interval', 'CMO', 'contract manufacturing organisation', 'CRA', 'clinical research associate', 'CRO', 'contract research organisation', 'C-SSRS', 'Columbia-Suicide Severity Rating Scale', 'CTR', 'clinical trial report', 'DLQI', 'Dermatology Life Quality Index', 'EASI', 'Eczema Area and Severity Index', 'EASI50', 'at least 50% reduction in EASI score', 'EASI75', 'at least 75% reduction in EASI score', 'EASI90', 'at least 90% reduction in EASI score', 'ECG', 'electrocardiogram', 'eCRF', 'electronic case report form', 'eDiary', 'electronic diary', 'ePRO', 'electronic patient-reported outcome', 'EQ-5D-5L', 'EuroQoL 5-Dimension Health Questionnaire 5 Level', 'GCP', 'Good Clinical Practice', 'HADS', 'Hospital Anxiety and Depression Scale', 'HCP', 'healthcare professional', 'HRQoL', 'health-related quality of life', 'ICF', 'informed consent form', 'ICH', 'International Council for Harmonisation', 'ID', 'identification number', 'IEC', 'independent ethics committee', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}